目的 探討曲克蘆丁腦蛋白水解物注射液聯(lián)合阿司匹林腸溶片治療煙霧病的臨床療效.方法 新疆醫(yī)科大學(xué)第一附屬醫(yī)院、新疆醫(yī)科大學(xué)第二附屬醫(yī)院、新疆自治區(qū)人民醫(yī)院2012年9月—2014年7月收治的煙霧病患者121例,隨機(jī)分為治療組(61例)和對照組(60例).對照組在常規(guī)治療的基礎(chǔ)上口服阿司匹林腸溶片,0.1 g/次,1次/d.治療組給予曲克蘆丁腦蛋白水解物注射液10 mL加入250 mL生理鹽水后緩慢靜脈點(diǎn)滴,1次/d.兩組均連續(xù)治療30 d.評價(jià)兩組的臨床療效,同時(shí)比較兩組神經(jīng)功能缺損(NIHSS)評分、顱內(nèi)供血、雙側(cè)平均肌力、凝血酶原時(shí)間和血小板計(jì)數(shù)的變化情況.結(jié)果 治療組和對照組的總有效率分別為83.61%、56.67%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05).治療10 d、治療后,兩組NIHSS評分均較治療前顯著降低,同組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05、0.01);且治療10 d、治療后治療組NIHSS評分顯著低于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05、0.01).治療10 d、治療后,兩組顱內(nèi)供血均較治療前顯著增加,同時(shí),患者雙側(cè)平均肌力均顯著升高,同組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.01);且治療組這些觀察指標(biāo)的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05、0.01).結(jié)論 曲克蘆丁腦蛋白水解物注射液聯(lián)合阿司匹林腸溶片對煙霧病有較好的臨床療效,能夠促進(jìn)患者神經(jīng)功能缺損恢復(fù),且不良反應(yīng)少,值得臨床推廣.

Objective To explore the effect of Troxerutin Cerebroprotein Hydrolysate Injection combined with Aspirin Enteric-coated Tablets in the treatment of moyamoya disease. Methods Patients (121 cases) with moyamoya disease who came to the First and Second Affiliated Hospitals of Xinjiang Medical University, and People's Hospital of Xinjiang Autonomous Region from September 2012 to July 2014 were randomly divided into control (60 cases) and treatment (61 cases) groups. The patients in the control group were po administered with Aspirin Enteric-coated Tablets on the basis of conventional treatment, 0.1 g/time, once daily. The patients in the treatment group were iv administered with 250 mL Troxerutin Cerebroprotein Hydrolysate Injection (10 mL adding into 0.9% saline solution), once daily. The patients in the two groups were treated for 30 d. After treatment, the treatment efficacy was evaluated, while the changes of NIHSS score, intracranial blood flow, average strength on both sides, prothrombin time, and platelet count in two groups were compared. Results The efficacies in the treatment and control groups were 83.61% and 56.67%, respectively, and there were differences between the two groups (P < 0.05). After 10 d treatment, NIHSS scores in the two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05, 0.01). NIHSS score in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05, 0.01). After 10 d treatment, intracranial blood flow in two groups were significantly increased, while the average muscle was significantly higher, and the difference was statistically significant in the same group (P < 0.01). These observational indexes in the treatment group improved more obviously than those in the control group in the same time of treatment, with the significant difference between two groups (P < 0.05, 0.01). Conclusion Troxerutin Cerebroprotein Hydrolysate Injection combined with Aspirin Enteric-coated Tablets has good clinical effect in the treatment of moyamoya disease, and can promote the neurologic deficits recovery with less adverse reaction, which is worthy of clinical application.